Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.

ABSTRACT: Affibody molecules are engineered scaffold proteins, which demonstrated excellent binding to selected tumor-associated molecular abnormalities in vivo and highly sensitive and specific radionuclide imaging of Her2-expressing tumors in clinics. Recently, we have shown that peptide nucleic acid (PNA)-mediated affibody-based pretargeted radionuclide therapy using beta-emitting radionuclide ¹⁷⁷Lu extended significantly survival of mice bearing human Her2-expressing tumor xenografts. In this study, we evaluated two approaches to use positron emission tomography (PET) for stratification of patients for affibody-based pretargeting therapy. The primary targeting probe Z_HER2:342-SR-HP1 and the secondary probe HP2 (both conjugated with DOTA chelator) were labeled with the posit

SUBMITTER: Vorobyeva A 

PROVIDER: S-EPMC6018533 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature